PDS's Versamune platform activates and directs the human immune system to unleash a targeted attack against cancer cells. The platform is designed to activate immune system T-cells to target diseased cells, with key projects including PDS0101 targeting HPV-associated cancers.
Cyborg Score Rationale
Recent VERSATILE-002 Phase 2 results showed promising median overall survival of 39.3 months and progression-free survival of 6.3 months in HPV16+ recurrent/metastatic head and neck cancer patients. However, the company remains in clinical stages with minimal revenue and high cash burn. Analyst price targets average $7.65-$8.33 with forecasts ranging from $4.54 to $15.75, suggesting significant upside potential if clinical trials succeed.
Top Insights
January 2026 FDA protocol amendment enables evaluation of PFS as earlier primary endpoint for potential accelerated approval while mOS remains required for full approval
Q3 2025 net loss was $9.0M with $26.2M cash on hand, indicating 2-3 years of runway at current burn rate
Pipeline includes PDS01ADC, an IL-12 tumor-targeted immune-cytokine enhancing T cell potency in tumor microenvironment
Company has collaboration agreements with NIH, Merck Eprova AG, and HHS
Named Competitors
Checkpoint inhibitors and CAR-T therapies — Established cancer immunotherapy leader
HPV cancer vaccines/immunotherapies — Competing cancer immunotherapy platform
Targeted cancer therapeutics — Clinical-stage cancer treatment company
Recent Developments
(January 2026) FDA protocol amendment for VERSATILE-003 trial changed primary endpoint to progression-free survival (PFS) for earlier evaluation and potential accelerated approval of PDS0101
(December 2025) Constructive Type C FDA meeting held to discuss proposed accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer
(November 2025) VERSATILE-002 Phase 2 trial completed with median overall survival 39.3 months and PFS of 6.3 months in CPS ≥1 patients
Open the full interactive PDS Biotechnology Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.